CHMP Recommends Avastin with Chemotherapy in Women with Platinum-Resistant Ovarian Cancer
Avastin is the first biologic medicine to receive a CHMP positive opinion for the most difficult to treat form of ovarian cancer.
Diabetes Care “Bundle” Produces Better Health Outcomes, AJMC Study Finds
Geisinger Health System’s use of a diabetes care system among high-risk patients produced lower risks of myocardial infarction, stroke and retinopathy over a three-year period, according to a study in The American Journal of Managed Care. Best of all, most of the benefit accrued in the first year of care.
Vaccine Could Boost Immune Attack Against Brain Tumors?
Scientists in Germany have developed a vaccine that they say provides some protection against brain tumors in mice.
Study Finds Low-Dose Aspirin Can Reduce the Risk of Pancreatic Cancer
The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Correcting The Blind Spot In Accountability: The Role Of Pharmacy Care
CMS stated that they seek recommendations about how the ACO program might evolve to “encourage greater care integration and financial accountability.”
Wearable Devices, mHealth Can Lead to True Patient Engagement
Smart watches, mHealth apps, and Bluetooth scales may just be edging into the social consciousness as a viable way to monitor personal health and manage chronic diseases, but EHR developers have been eyeing these technologies for some time, seeing them as valuable tools in the struggle to engage patients, prevent unnecessary readmissions, reduce costs, and promote long-term health.
Hospital Outpatient Prices Sharply Higher than Docs', Study Finds
Hospital outpatient prices for standard blood tests, cancer screening and other services varied widely and were sharply higher, on average, than prices charged by ambulatory clinics and independent doctors, an analysis of autoworker health-plan spending across 18 cities has found.
FDA Panel Wants More Data for Astra's Olaparib
Safety concerns over the PARP inhibitor warranted the request for additional data.
Transitioning to Bundled Payments
Taking a more strategic approach to payer relationships may be the key to surviving new reimbursements models.
AJAC Highlights Potential of Connected Care, Patient-Centered Ways to Measure Quality
The June issue of The American Journal of Accountable Care discusses the potential of “connected care,” to improve access and cut costs, and proves how what patients say will matter when measuring quality. The publication, from The American Journal of Managed Care, is devoted to research and commentary on healthcare reform.
In Push to Extend Medicaid Pay Bump, Docs Downplay ACA Link
Physician groups are lobbying hard to extend an Obamacare provision that requires state Medicaid programs to pay primary-care physicians at higher Medicare rates to improve access for Medicaid patients. But to persuade congressional Republicans to go along, they are downplaying the fact that the pay bump is part of the Patient Protection and Affordable Care Act.
Nivolumab Trial Halted Early: Promising Phase 3 Results in Advanced Melanoma
Results indicate that nivolumab is likely to prolong survival in advanced melanoma.
Disappointment for Advanced NSCLC Patients Expressing EGFR WT
Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer (NSCLC) in patients with wild-type epidermal growth-factor receptor (EGFR) tumour status.
Drug Discount Program Has Drugmakers Crying Foul
This spring as the feds have been drawing up new rules for the program, a pitched battle has broken out between hospitals and drug manufacturers who say the program, known as 340B, is now bloated and badly regulated.
ACO Coalition Members Share Best Practices
The American Journal of Managed Care followed up the first meeting of its ACO and Emerging Healthcare Delivery Coalition with its first interactive conference call, which was open to all members. Anthony Slonim, MD, DrPH, a Coalition co-chair who on July 1 will become president and CEO at Renown Health in Reno, Nev., moderated the roundtable discussion.
FDA Questions the Efficacy of Astra's PARP Inhibitor in Ovarian Cancer Treatment
The FDA staff report questioned the unusually poor performance of the control group used in the study.
Autologous Stem Cell Transplant Can Improve Survival in MM Patients
Newly diagnosed multiple myeloma patients undergoing ASCT showed a significant improvement in survival.
FDA Warns of Intoxication Following IV Docetaxal
The US FDA has warned that intravenous administration docetaxal formulations contain alcohol and may cause intoxication among patients. A product label revision is being made.
Legislation Would Factor Patient Finances into Readmission Penalities
The Senate introduced legislation this week that would require Medicare to consider patients' finances when deciding whether to punish a hospital for readmission numbers.
VA Governor to Bypass Lawmakers, Expand Medicaid
Virginia Gov. Terry McAuliffe vowed Friday to bypass the General Assembly and expand Medicaid eligibility for about 400,000 low-income residents on his own.
By 2020, Most States Will Be on the Federal Exchange
I’ll say it: I think most states, if not all, will be on the Federal exchange by the end of the decade.
Newfound Risk That Providers, Payers, and Patients Are Navigating With the Implementation of the Affordable Care Act
A panel asks: “Due to the ACA, who is now presenting with cancer? Who is walking through the door and is there a difference between patients since the ACA implementation?”
Consumer Group Urges Hospitals To Stop Promoting Questionable Screenings
Consumer advocacy group Public Citizen on Thursday called on 20 hospital systems to stop partnering with companies that offer low-cost screenings for heart disease and stroke risk, saying the promotions are “unethical” and the exams are more likely to do harm than good.
Anti-CD20 Antibody Improves Lenalidomide Performance in CLL
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.
Need Better Representation of Women and Minorities in Trials: Democrats
Twenty-two Democratic lawmakers have asked the National Institutes of Health to publicly disclose demographic data for all clinical trials posted on